MASHINIi

Prelude Therapeutics Incorporated.

PRLD.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Prelude Therapeutics Incorporated is a clinical-stage biopharmaceutical company focused on discovering and developing novel, small molecule therapies to treat cancer. The company's pipeline includes drug candidates targeting key drivers of cancer cell growth, survival, and resistance. Prelude Therap...Show More

Ethical Profile

Mixed.

Prelude Therapeutics, a clinical-stage oncology company, focuses on developing precision medicines for cancers with unmet needs, including SMARCA2 degraders and a CDK9 inhibitor. The company is recognized for its leading SMARCA-targeted pipeline and first KAT6A selective degraders, with multiple milestones anticipated in 2025. However, its ethical profile is mixed. Critics point to the inherent reliance on animal testing in preclinical drug development, which creates a significant negative impact on animal welfare. Furthermore, there is currently no public data available regarding drug pricing, accessibility, fair labor practices, supply chain ethics, or environmental impact, making a comprehensive assessment challenging.

Value Scores

Better Health for All50
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-20
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

50

Prelude Therapeutics is a clinical-stage biopharmaceutical company entirely focused on discovering and developing novel, small molecule therapies to treat cancer, addressing high unmet medical needs.

1
This means 100% of its business is devoted to health improvement. The company's entire capital allocation and R&D budget are dedicated to developing these novel drug candidates, including SMARCA2 and KAT6A degraders, Precision ADCs, and other discovery programs.
2
The company has multiple milestones planned for 2025 and 2026, including monotherapy updates, combo data, interim phase 1 data, pre-clinical data, candidate selection, and IND submissions.
3
It is described as having the 'industry’s leading SMARCA-targeted pipeline' and the 'industry’s first KAT6A selective degraders'.
4

Fair Money & Economic Opportunity

0

No evidence available to assess Prelude Therapeutics Incorporated on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

The provided articles do not contain specific, concrete data points for any of the KPIs related to Fair Pay & Worker Respect, including living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.

1

Fair Trade & Ethical Sourcing

0

No evidence available to assess Prelude Therapeutics Incorporated on Fair Trade & Ethical Sourcing.

Honest & Fair Business

0

No evidence available to assess Prelude Therapeutics Incorporated on Honest & Fair Business.

Kind to Animals

0

Prelude Therapeutics Incorporated engages in animal testing.

1
However, the provided articles do not offer specific quantitative data or details regarding the extent of animal testing, the number of animals used, the company's animal testing policy, or any efforts related to alternative testing methods, humane certifications, or conservation impacts. Therefore, no KPIs can be scored based on the available evidence.

No War, No Weapons

0

No specific data relevant to Prelude Therapeutics Incorporated's involvement in arms manufacturing, military contracts, conflict facilitation, or peace initiatives was found in the provided articles. The documents focus on financial information, clinical trial data for cancer therapies, and corporate governance, without addressing any of the metrics related to the 'No War, No Weapons' value.

1

Planet-Friendly Business

-20

The company reported no specific regulatory actions, violations, fines, or compliance issues for the quarter ended March 31, 2021.

1
Other articles, primarily financial reports and general ESG risk summaries, do not provide specific quantitative data points for any other 'Planet-Friendly Business' KPIs, such as carbon emissions, renewable energy usage, water consumption, waste diversion, or climate targets.

Respect for Cultures & Communities

0

No evidence available to assess Prelude Therapeutics Incorporated on Respect for Cultures & Communities.

Safe & Smart Tech

0

The company explicitly states compliance with GDPR, HIPAA, and CCPA.

1
However, its mention of the EU-US Privacy Shield is outdated, as it was declared invalid in 2020.
2
The company has a policy to notify clients of data breaches within 72 hours, with clients responsible for individual notifications.
3
It also provides a data access request mechanism for users to view and request changes to their data.
4
Encryption of data in transit and at rest is mentioned, and employee training on HIPAA compliance is conducted.
5
No specific data is available on the frequency or severity of data breaches, cybersecurity investment, privacy certifications, security training effectiveness metrics, AI ethics, algorithmic transparency, unauthorized data use incidents, authentication security, vulnerability management, bug bounty programs, privacy by design, security testing coverage, data minimization practices, algorithmic harm remediation, or digital rights advocacy.
6

Zero Waste & Sustainable Products

0

No relevant evidence was found in the provided articles to assess Prelude Therapeutics Incorporated against the 'Zero Waste & Sustainable Products' ethical value. Both articles explicitly stated that no data could be extracted as the requested pages were not found or did not exist.

1

Own Prelude Therapeutics Incorporated?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.